Copyright
©The Author(s) 2021.
World J Diabetes. Nov 15, 2021; 12(11): 1942-1956
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1942
Published online Nov 15, 2021. doi: 10.4239/wjd.v12.i11.1942
Table 1 Baseline parameters analysis according to cardiovascular risk groups derived from advanced glycation endproducts result
Parameter | None/limited CV risk (n = 99) | Increased/definite CV risk (n = 174) | Total (n = 273) | P value1 |
Male gender, n (%) | 41 (41.4) | 96 (55.2) | 137 (50.2) | 0.029 |
Age (yr) | 67.6 ± 12.4 | 69.1 ± 11.8 | 68.5 ± 12.1 | 0.313 |
Disease duration (yr) | 9.0 (3.0-18.0) | 14.0 (6.0-21.0) | 12.0 (5.0-20.0) | 0.005 |
BMI (kg/m2) | 29.2 ± 4.96 | 29.1 ± 4.85 | 29.2 ± 4.88 | 0.900 |
Neck circumference (cm) | 38.7 ± 4.01 | 39.1 ± 4.17 | 38.9 ± 4.11 | 0.409 |
Waist circumference (cm) | 98.1 ± 12.7 | 97.8 ± 12.7 | 97.9 ± 12.6 | 0.870 |
Hip circumference (cm) | 106.3 ± 9.5 | 105.5 ±10.5 | 105.8 ± 10.1 | 0.531 |
WHR | 0.92 ± 0.07 | 0.93 ± 0.08 | 0.92 ± 0.08 | 0.575 |
Smokers, n (%) | 12 (12.1) | 41 (23.6) | 53 (19.4) | 0.022 |
Physical activity, n (%) | ||||
Not physically active | 15 (15.2) | 56 (32.2) | 71 (26.0) | 0.008 |
1-4 ×/mo | 24 (24.2) | 36 (20.7) | 60 (22.0) | |
> 4 ×/mo | 60 (60.6) | 82 (47.1) | 142 (52.0) | |
Therapy, n (%) | ||||
OHA | 56 (56.6) | 90 (51.7) | 146 (53.5) | 0.619 |
Insulin | 14 (14.1) | 26 (14.9) | 40 (14.7) | |
OHA + insulin | 23 (23.2) | 49 (28.2) | 72 (26.4) | |
GLP-1 based therapy | 2 (2.0) | 6 (3.4) | 8 (2.9) | |
No medications | 4 (4.0) | 3 (1.7) | 7 (2.6) | |
HbA1c (%) | 7.2 (6.5-8.5) | 7.65 (6.8-8.8) | 7.4 (6.7-8.8) | 0.041 |
- Citation: Grahovac M, Kumric M, Vilovic M, Martinovic D, Kreso A, Ticinovic Kurir T, Vrdoljak J, Prizmic K, Božić J. Adherence to Mediterranean diet and advanced glycation endproducts in patients with diabetes. World J Diabetes 2021; 12(11): 1942-1956
- URL: https://www.wjgnet.com/1948-9358/full/v12/i11/1942.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i11.1942